soul trial oral semaglutide cardiovascular outcomes 2024 2025 results soul trial oral semaglutide cardiovascular outcomes results 2024 2025 Oral Cardio-kidney-metabolic protective effects of semaglutide

Your Body Will Thank You

Activates both GLP-1 and GIP receptors, offering broader metabolic effects and potentially better appetite control

Taking a small amount daily is more effective for regularity than taking a large amount once a week

Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer

Changes in Macronutrient Processing: Studies have shown that GLP-1 receptor activation enhances insulin sensitivity, shifting the bodys preference towards fat oxidation rather than glucose reliance

Take a Gentle Walk A short, comfortable walk may help gas move